EMMAC Life Sciences Group announced that in partnership with Boiron, it has been selected by the French Agency for the Safety of Medicines and Health Products as one of the suppliers for the forthcoming French Medical Cannabis trial. The trial, the first of its kind in France, will allow 3,000 patients access to medical cannabis as a treatment option for certain indications; including chronic pain, epilepsy, oncology and spasticity; under tightly controlled conditions. ANSM has selected EMMAC's 20/1 and 10/10 oral solutions as second-source treatments to be available to patients and healthcare professionals as part of the two year trial. The partnership combines Boiron's unparalled expertise in plant-based medicine, with EMMAC's uniquely controlled European supply chain, from seed to patient, in order to deliver pharmaceutical-grade cannabis medicines that meet the strict requirements of product quality, safety and traceability.